정부/공공기관
임상시험센터
CRO
분석CRO/센트럴랩
유관기관/협회
정보서비스
해외 유관 기관
* CRO 게재 기준: CRO자율등록 기관
ClinicalTrials.gov에 등록된 정보를 기준으로 코로나-19(COVID-19) 관련 글로벌 임상시험 현황을 제공합니다.
전체 2550건이 검색되었습니다.
| No. | Status | Study Title | Conditions | Interventions | Phase | Sponsor/Collaborators | Funder Type | Number Enrolled | Sex | Age | Locations |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1143 | Recruiting | IRAK 4 Inhibitor (PF-06650833) in Hospitalized Patients With COVID-19 Pneumonia and Exuberant Inflammation. | COVID-19 Pneumonia | Drug: PF-06650833 Drug: Matching Placebo |
Phase 2 | Giovanni Franchin, M.D, Ph.D, Pfizer | OTHER | 68 | All | 18 Years | Bronx-Lebanon Hospital Center Health Care System, Bronx, New York, United States |
| 1142 | Terminated | IRAK4 Inhibition in Treatment of COVID-19 With ARDS (I-RAMIC) | COVID-19 | Drug: PF-06650833 Drug: Placebo |
Phase 2 | Yale University, Pfizer | OTHER | 7 | All | 18 Years ~ 75 Years | Yale New Haven Hospital, New Haven, Connecticut, United States |
| 1141 | Not yet recruiting | Isatuximab, Velcade, and Dexamethasone in Patients With Multiple Myeloma and Severe KIDNEY Disease | Multiple Myeloma | Drug: Isatuximab Drug: Bortezomib Drug: Dexamethasone |
Phase 1 | Washington University School of Medicine, Sanofi | OTHER | 28 | All | 18 Years | Washington University School of Medicine, Saint Louis, Missouri, United States |
| 1140 | Recruiting | Isavuconazole for the Prevention of COVID-19-associated Pulmonary Aspergillosis | Aspergillosis Invasive | Drug: Isavuconazonium Injection [Cresemba] Drug: Placebo |
Phase 3 | Jeffrey Jenks, MD, MPH, Astellas Pharma Global Development, Inc. | OTHER | 162 | All | 18 Years | University of California Irvine, Orange, California, United States University of California Davis, Sacramento, California, United States University of California San Diego, San Diego, California, United States |
| 1139 | Not yet recruiting | Isotretinoin in Treatment of COVID-19 | COVID-19 | Drug: Isotretinoin Only Product in Oral Dose Form | Phase 3 | Tanta University | OTHER | 300 | All | 18 Years ~ 40 Years | |
| 1138 | Recruiting | I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients | COVID-19 | Drug: Remdesivir Drug: Pulmozyme Drug: IC14 Drug: Celecoxib Famotidine Drug: Narsoplimab Drug: Aviptadil Acetate Drug: Cyclosporine |
Phase 2 | QuantumLeap Healthcare Collaborative, University of California, San Francisco, University of Pennsylvania, Emory University, University of Alabama at Birmingham, University of Colorado, Denver, University of Southern California, Yale University, Columbia University, Wake Forest University Health Sciences, Sanford Health, Long Beach Memorial Medical Center, Georgetown University, Kalispell Regional Medical Center, Montefiore Medical Center, University of California, Davis, Hoag Memorial Hospital Presbyterian, University of Iowa, Main Line Health, Northwestern University | OTHER | 1500 | All | 18 Years | University of Alabama at Birmingham, Birmingham, Alabama, United States UC Davis Medical Center, Davis, California, United States Long Beach Memorial Medical Center, Long Beach, California, United States University of Southern California, Los Angeles, California, United States Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States University of California San Francisco (UCSF), San Francisco, California, United States University of Colorado, Aurora, Colorado, United States Yale Cancer Center, New Haven, Connecticut, United States Georgetown University, Washington, District of Columbia, United States Emory University, Atlanta, Georgia, United States Northwestern University, Chicago, Illinois, United States University of Iowa, Iowa City, Iowa, United States Kalispell Regional Medical Center, Kalispell, Montana, United States Montefiore Medical Center, Bronx, New York, United States Columbia University Medical Center, New York, New York, United States Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, North Carolina, United States University of Pennsylvania (U Penn), Philadelphia, Pennsylvania, United States Main Line Health - Lankenau Medical Center, Wynnewood, Pennsylvania, United States Sanford Health, Sioux Falls, South Dakota, United States |
| 1137 | Completed | Ivermectin as a Novel Therapy in COVID-19 Treatment | COVID | Drug: Ivermectin | Phase 3 | Tanta University | OTHER | 164 | All | Sherief Abd-Elsalam, Tanta, Egypt |
